Institutional members access full text with Ovid®

Share this article on:

Excellent Long-Term Survival in Patients With Early-Stage Primary Bone Lymphoma Treated With Doxorubicin-Based Chemotherapy and Local Radiotherapy.

Stein, Moshe Efraim M.D.; Epelbaum, Ron M.D.; Zaidan, Jamal M.D.; Kuten, Avraham M.D.; Ben-Schachar, Menachem M.D.; Haim, Nissim M.D.

American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - pp 603-605
Article

Primary bone lymphoma accounts for less than 5% of primary extranodal presentations, and the majority are of the diffuse, large cell, B-cell type. The study presents the authors' 21 years of experience (1979-2000) in ten patients with early stage (IE-IIE) primary bone lymphoma. All patients were treated with doxorubicin-based chemotherapy. Seven received consolidation radiotherapy to an area encompassing the primary tumor with generous margins, including the adjacent soft tissues, and in two stage IIE patients also to the regional lymph nodes. Mean total dose was 3989 cGy. Nine patients are alive with no evidence of recurrent disease. There are no severe late side effects, and only one patient died due to therapy-resistant small cell lung cancer (second primary), while in complete remission from his primary lymphoma. Albeit retrospective in nature with a small patient accrual, this study demonstrates that primary bone lymphoma is a curable disease following aggressive doxorubicin-based chemotherapy. The exact rule of radiation therapy is yet to be determined.

From the Department of Oncology (M.E.S., R.E., A.K., N.H.) and Radiotherapy Unit (M.E.S., A.K.), Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa; Oncology Unit, Nahariya Municipal Hospital (M.B.-S.), Nahariya; and Oncology Unit, Rebecca Sieff Hospital (J.Z.), Safed, Israel.

Address correspondence and reprint requests to Dr. M. E. Stein, Department of Oncology, Rambam Medical Center, Haifa 31096, Israel. E-mail: m_stein@rambam.health.gov.il

© 2002 Lippincott Williams & Wilkins, Inc.